Conclusion: Bitter melon effectively boosted GLP-1 secretion, leading to better blood sugar control alongside traditional medication
Approved uses for Ozempic, Wegovy, and Rybelsus are not the same
A large observational study published in mid-2025 reported that diabetic patients using GLP-1 drugs experienced a two- to threefold increased risk of developing nAMD compared to non-users
By activating both pathways, a dual agonist can produce a more powerful effect on appetite suppression and metabolic function than a GLP-1 agonist alone
The tirzepatide unit conversion guide helps with accurate dosing, and our coverage of oral tirzepatide explores emerging delivery methods
Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, Faraci G, Pacetti D, Vivarelli M, Nicolini D, Garelli P, Casini A, Manco M, Mingrone G, Risaliti A, Frega GN, Benedetti A, Gastaldelli A